

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Article Title: Transcriptomic profile of normal breast tissue post-mifepristone treatment: secondary outcomes of a randomized controlled trial

Deborah Utjés^{1,4¶}, Nageswara Rao Boggavarapu^{1¶}, Mohammed Rasul^{1,2}, Isabelle Koberg¹, Alexander Zulliger¹, Sakthivignesh Ponandai-Srinivasan¹, Carolina von Grothusen¹, Parameswaran Grace Lalitkumar¹, Kiriaki Papaikonomou^{1,4}, Twana Alkasalias^{1,3*} and Kristina Gemzell-Danielsson^{1,4,5*}

¹Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

²Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University, Erbil, Kurdistan Region, Iraq

³General Directorate of Scientific Research Center, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq.

⁴Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden

⁵WHO Collaborating Centre, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden.

¶ Equally contributed authors.

* Equally contributed authors

26 **Corresponding Author:**

27 Twana Alkasalias

28 Assistant professor, Ph.D. in cell and tumor biology, Department of Women's and Children's

29 Health, Karolinska Institutet

30 Biomedicum 4A, Solnavägen 9, 17165, Solna, Stockholm, Sweden

31 Phone: +46 7 39 5581 29

32 Email: twana.alkasalias@ki.se

33

34

35

36 **Author contributions**

37 **DU:** study design, data collection, interpretation, and manuscript writing. **NB:** data acquisition,

38 designed experiments and analyzed RNA seq data. **MR, IK, AZ, SPS,** and **CvG:** Experimental

39 work, and manuscript reviewing. **PGL:** study design, material collection, manuscript writing

40 and reviewing **KP:** material collection, manuscript writing and reviewing. **TA:** Conception,

41 study design, data collection & visualization, analysis, interpretation, and manuscript writing.

42 **KGD:** Conception, study design, sample collection, critical comments, manuscript writing and

43 funding.

44

45

46

47

48

49

50

51 **Running Title:** Impact of mifepristone on breast tissue

52

53 **Article type:** Clinical trial

54

55 **Funding Statement:** This study was funded by the Swedish Research Council (2012-01981,
56 2017-00932), the Swedish Cancer foundation (5321-9416) and the joint grant from Stockholm
57 County Council and Karolinska Institutet (ALF).

58

59 **Disclosure Statement:** The authors have no potential conflicts of interest.

60

61

62 **Data Sharing Statement:** The raw data and processed data files were submitted to Gene
63 Expression Omnibus database with the GEO accession ID GSE252145 (for reviewer access
64 please go to <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252145>, Enter token
65 qfqnyscmvzmzjep into the box).

66

67

68 **Trial registration:**

69 Clinical Trial Registration Number: NCT01931657

70 URL: <https://classic.clinicaltrials.gov/ct2/show/NCT01931657>

71 Date of registration: 20/07/2009

72 Date of enrollment of the first subject: 24/11/2009

73

74

75

76 **Capsule:**

77 Mifepristone may provoke a protective effect against breast carcinogenesis; an enrichment in
78 extracellular matrix signaling pathways and an association with breast cancer, particularly
79 progesterone receptor positive cases, were observed.

80

81 **Abstract**

82 Progesterone receptor antagonism is gaining attention due to progesterone's recognized role as
83 a major mitogen in breast tissue. Limited but promising data suggest the potential efficacy of
84 antiprogestins in breast cancer prevention. The present study presents secondary outcomes from
85 a randomized controlled trial and examine changes in breast mRNA expression following
86 mifepristone treatment in healthy women. We analyzed 32 paired breast biopsies from 16
87 healthy premenopausal women at baseline and after two months of mifepristone treatment. In
88 total, twenty-seven differentially expressed genes were identified, with enriched biological
89 functions related to extracellular matrix remodeling. Notably, the altered gene signature
90 induced by mifepristone *in vivo* was rather similar to the *in vitro* signature. Furthermore, this
91 expression gene signature was associated with breast carcinogenesis and significantly
92 correlated with progesterone receptor expression status in breast cancer, as validated in The
93 Cancer Genome Atlas dataset using the R2 platform. The present study is the first to explore
94 the breast transcriptome following mifepristone treatment in healthy breast tissue *in vivo*,
95 enhancing the understanding of progesterone receptor antagonism and its potential protective
96 effect against breast cancer by investigating its action in healthy breast tissue.

97

98

99 **Keywords**

100 Mifepristone, progesterone signaling, progesterone receptor antagonist, breast cancer

101 ***Introduction***

102 The majority of breast cancers are related to reproductive factors (1), implicating endogenous
103 cyclic hormonal exposure affecting breast tumorigenesis. Progesterone has emerged as a major
104 mitogen since proliferation of breast epithelial cells occur during the progesterone-dominated
105 luteal phase (2-4). Among different epithelial cell subtypes, the luminal progenitors serve as
106 breast cancer precursor cell (5). Progesterone acts primarily via a paracrine mechanism to
107 stimulate proliferation of the dominating progesterone receptor (PR)-negative breast cells (2),
108 largely mediated by the downstream mediators RANK-L and WNT4 (3, 6, 7).

109 High mammographic density (HMD) is another important risk factor of breast cancer (8, 9).
110 Therefore, the architecture and the crosstalk between the stroma including the extracellular
111 matrix (ECM) and epithelial cells in the context of progesterone exposure, play a vital role in
112 breast cancer initiation process.

113 The mitogenic action of progesterone can be counteracted by PR modulators. There is
114 promising but limited data suggesting the potential efficacy of antiprogestosterone in breast cancer
115 prevention (10, 11). Nevertheless, numerous studies have investigated the use of a low
116 continuous dose of antiprogestosterone in benign gynecological conditions and breast cancer
117 treatment (12) . We hypothesized that antagonizing progesterone signaling may protect against
118 breast carcinogenesis, warranting further clinical and molecular investigations. As a secondary
119 outcome of our randomized controlled trial (RCT) (13), we studied the effects of the PR-
120 antagonist mifepristone on normal breast tissue following two months of treatment in healthy
121 premenopausal women.

122

123

124

125

126 ***Materials and methods***

127 This study reports the secondary outcome of a prospective, double blind, placebo-controlled
128 RCT with the main outcome to study the impact of pretreatment with a continuous low dose of
129 mifepristone on menstrual bleeding patterns in women opting for a levonorgestrel releasing
130 intrauterine device for contraception where the results are published by our group elsewhere
131 (13). The secondary outcome presented here, was to investigate the effect of mifepristone
132 treatment on breast tissue. The study was conducted at Karolinska University Hospital,
133 Stockholm, Sweden from 2009 until 2015 and was approved by the Swedish Medical Products
134 Agency (EudraCT number 2009-009014-40). The study protocol was designed according to the
135 recommendations in the CONSORT statement and was approved by the ethical committee at
136 Karolinska Institutet (Dnr: 2009/144-31/4) prior to recruitment. The trial was registered at
137 clinicaltrials.gov (NCT01931657).

138

139 ***Subjects***

140 Eligible study subjects were healthy premenopausal women aged 18-43 years with regular
141 menstrual cycles lasting 25-35 days and with no contraindications to any of the study
142 treatments. All exclusion criteria are presented in the original study, including use of any
143 hormonal or intrauterine contraception and pregnancy, or breastfeeding two months prior to the
144 study or a history of breast cancer or other malignancies. The trial chart explains the details of
145 the enrolled subjects in the current cohort (Figure S1) and baseline characteristics of the women
146 contributing to paired breast biopsies analyses are presented in Table S1.

147

148 ***Treatment***

149 Study subjects were randomized into two treatment groups (13). One group was treated with
150 50 mg mifepristone (one quarter of 200 mg Mifegyne®, Exelgyn) every other day for two

151 months (56 days) starting on the first day of the menstrual cycle. The comparator group received
152 visually indistinguishable B-vitamin tablets (TrioBe® Recip) which were also divided into four
153 parts. For the purpose of the present study, only paired breast samples from the mifepristone
154 treated group were analyzed.

155

156 *Biopsy collection*

157 Core needle breast aspiration biopsies were collected at baseline and at the end of the treatment,
158 under ultrasound guidance from the upper outer quadrant of one breast using a 14-gauge needle
159 with an outer diameter of 2.2 mm. The collected breast tissue was divided into two parts, snap-
160 frozen and stored at -180°C until further processing.

161 In order to do a functional validation with an *in vitro* experiment, we used breast tissue samples
162 from three additional healthy and premenopausal women undergoing mammoplasty procedure.
163 This collection was performed according to a separate study, approved by the ethical committee
164 at Karolinska Institutet (Dnr: 2021-04144) prior to recruitment.

165

166 *RNA extraction*

167 RNA extraction was performed from 16 paired samples (i.e. 32 samples) using the Purelink™
168 RNA Micro kit in conjunction with TRIzol reagent (Life Technologies). For *in vitro* studies,
169 the RNA extraction from primary breast cells was performed using Quick-DNA/RNA™
170 Microprep Plus; Zymoresearch. RNA quantification was done using the Qubit RNA High
171 Sensitivity Assay Kit (Invitrogen/ Thermo Fischer).

172

173 *cDNA library construction and sequencing*

174 Complementary DNA (cDNA) libraries for NGS were constructed from RNA for the 16 paired
175 samples, before and after mifepristone treatment, using the well-established Smart-seq2

176 protocol (14), and been well optimized in our group (15).

177

178 *RNA-sequencing data processing and analysis*

179 Quality check of raw sequencing reads was done with FastQC and MultiQC (16). RNA
180 sequencing (RNA-seq) data analysis was performed with the Partek Flow Genomic Analysis
181 Software (Partek Inc., St. Louis, Missouri, USA). The detailed analysis optimized by our group
182 is mentioned in von Grothusen et al (15)

183

184 *Gene ontology and pathway analysis*

185 GO analyses for the functional annotation of the DEGs and enriched pathway analysis were
186 conducted using the g:Profiler database (version e101_eg48_p14_baf17f0) with Benjamini-
187 Hochberg FDR multiple testing correction method applying significance threshold of 0.05 (18).
188 Reactome pathway analysis (19) and Metascape-designet database (20) were also used.

189

190 *RT-PCR analysis*

191 The extracted RNA samples were converted to cDNA using SuperScript[®] VILO[™] kit
192 (Invitrogen[®], Thermo Fisher Scientific, Waltham, USA). We validated technically some
193 significantly altered genes obtained by sequencing using Taqman[®] gene probes namely *CCL18*
194 (assay ID: Hs00268113_m1), *MMP2* (assay ID: Hs01548727_m1), *COL1A1* (assay ID:
195 Hs00164004_m1), *COL1A2* (assay ID: Hs01028956_m1), *COL3A1* (assay ID:
196 Hs00943809_m1), and *18s* (4319413E) as housekeeping gene (Thermo Fisher Scientific,
197 Waltham, USA). We designed a customized primer sequence for ADAMTS2-1 (Forward
198 primer sequence ‘cctgacaaccctacttttgc’; reverse primer sequence ‘tgaggatgtcaggtgtcagc’) and
199 performed RT-PCR using Sybr-green PCR assay. 20ng of cDNA from 10 samples was used in
200 triplicates in the RT-PCR and analyzed on a One Step Plus Real-time PCR system (Applied

201 Biosystems, USA) according to the manufactures protocol. Fold change was calculated using
202 the comparative Ct-method. A paired t-test compared the pre- and post-mifepristone treatment
203 groups. To assess the impact of different doses of mifepristone on breast cells in vitro, a two-
204 way ANOVA test was applied after the square root transformation. Significance was considered
205 at a P-value < 0.05. GraphPad Prism 9.1.2 (GraphPad Software Inc., USA) was utilized for the
206 statistical analyses.

207

208 *In vitro validation via primary epithelia cell isolation*

209 After breast tissue collection and examination by pathologist, the sample was transferred for
210 tissue digestion and single cells isolation. In brief, the tissue was diced on ice using BSS and
211 DMEM with HEPES. The small tissue fragments were transferred to a mixture of digestion
212 enzymes (hyaluronidase and collagenase 1) and incubated on a rotator at 37°C for 4-18 hours.
213 The digested tissue was then filtered through a 100 µM strainer, and the resulting flowthrough
214 was cultured using a cocktail of Epicult and mammary media.

215

216 *Immunofluorescence*

217 Following cell isolation, a total of 50,000 cells were seeded per well in 8-well NuncLab-Tek
218 Chamber Slides (Sigma) and incubated for 72 hours at 37°C in a 5% CO₂ incubator.
219 Subsequently, the cells were fixed with 4% paraformaldehyde for 15 minutes at room
220 temperature and then blocked with 2% BSA and 0.1% Triton-X (Sigma) in PBS for 30 minutes
221 at room temperature. Subsequently, the cells were incubated with primary antibodies (CD49f,
222 Rat, #MA5-16884, ThermoFisher Scientific; EPCAM, Goat, R and D Systems Cat# AF960,
223 RRID:AB_355745; CK8, Mouse, Santacruz, sc-8020; CK14, Rabbit, Invitrogen, # MA5-
224 32214) in 2% BSA in PBS for 1 hour at RT. After three washes with PBS, the cells were

225 incubated with the respective secondary antibodies (Alexa Fluor; Donkey anti-Rat 488, Donkey
226 anti-Goat 594, Donkey anti-Mouse 488, and Goat anti-Rabbit 594) in 2% BSA in PBS for 30
227 minutes at RT. Finally, the samples were mounted using ProLong Gold Antifade Mounting
228 Medium with DAPI.

229

230 *In vitro drug treatment assay*

231 Primary isolated breast epithelial cells were cultured at a density of 5×10^4 cells per well in a
232 12-well plate. On the following day, these cells were subjected to different concentrations of
233 mifepristone treatment (0, 5, 50, and 100 μM) for a duration of three days. Subsequently, the
234 cells were collected, and their lysates were prepared at three distinct time points: the baseline
235 before the initiation of treatment, after one-day of treatment, and upon the completion of the
236 three-day treatment period. To ensure robustness and reliability, we employed cells from three
237 different donors for this study. For each experiment, we conducted three independent replicates.

238

239 *In silico data analysis*

240 We employed the R2 Genomics Analysis and Visualization Platform (21) for conducting
241 comparative transcriptomic analysis. This online resource facilitated the examination and
242 assessment of the enrichment gene signature within the breast cancer cohort obtained from
243 TCGA. The user-friendly interface and comprehensive tools provided by R2 allowed for
244 efficiently exploring and statistically validating each gene within the enriched gene cohort. Our
245 approach involved evaluating the differences between normal breast tissue and breast cancer,
246 along with an exploration of their correlation with PR expression and signaling. To ensure
247 statistical robustness, we applied a T-test with false discovery rate correction as a multiple
248 testing approach, employing a P-value cutoff of 0.05.

249 **Results**

250 ***Modulation of gene expression by mifepristone enriches ECM signaling pathways in normal***
251 ***breast tissue***

252 We compared the gene expression profile in normal breast tissue before and after mifepristone
253 treatment. A false discovery rate (FDR) of ≤ 0.05 and fold change (FC) of ≥ 2 or ≤ -2 was
254 considered statistically significant and identified 27 differentially expressed genes (DEGs) of
255 which 19 genes were upregulated and 8 genes were downregulated (Table S2). We grouped the
256 27 DEGs and named them Gene signature Enriched to Mifepristone's action on normal Breast
257 (GEM-B). GEM-B represents a set of genes responsive to mifepristone in normal breast tissue.
258 A volcano plot displaying GEM-B among overall gene expression is presented in Figure S2A.
259 To technically validate RNA-seq data at the individual gene level, we employed real-time (RT)-
260 PCR on the same RNA extracted samples for several genes from the GEM-B (Figure S2B). In
261 line with the transcriptome analysis, the mifepristone treated samples exhibited a significant
262 upregulation of the six validated genes by RT-PCR.

263 To explore the biological context of the DEGs, gene functional enrichment analysis were
264 performed using the g:Profiler database. The results of the top five terms in each of the three
265 Gene Ontology (GO) categories (BP: biological process; CC: cellular component, MF:
266 molecular function) annotated in the database are presented in Table 1. The Reactome pathway
267 analysis demonstrated the upregulated DEGs significantly enriched in 54 biological processes.
268 The top ten of those, were mainly associated with ECM organization (Table S3). The same
269 analyses with the downregulated DEGs revealed one significantly enriched term in the GO
270 functional annotation (ontology: MF), namely 'active borate transmembrane transporter
271 activity' with the involvement of solely gene SLC4A1. In the Reactome pathway analysis, there
272 were two genes involved separately in six pathways; gene IL1B (involved in
273 'CLEC7A/inflammasome pathway', 'Interleukin-1 processing', 'cell recruitment' and

274 ‘purinergic signaling in leishmaniasis infection’ and gene LAMA1 (involved in ‘laminin
275 interactions’ and ‘MET activates PTK2 signaling’.

276 The analysis was validated via a third database, Metascape-designet database. The data set
277 enrichment from designet pathway indicated similarly the enrichment of ECM-related
278 pathways (Figure S3).

279

280 ***The in vivo effect of mifepristone is comparable to its in vitro effect on normal breast tissue***

281 To further validate the *in vivo* changes in the transcriptomic signature induced by mifepristone
282 treatment, we isolated primary breast epithelial cells and exposed them to varying
283 concentrations of mifepristone (0, 5, 50, and 100 μ M) during two different treatment periods
284 (one and three days), to study the dose response effect as well as the influence of duration of
285 treatment.

286 First, we characterized the primary isolated cells and assessed the enrichment of distinct
287 epithelial cell subtypes including luminal progenitor, mature luminal, basal, and other stromal
288 cells. The expression of four protein markers (EPCAM, CD49f, CK8, and CK14) was examined
289 (22). Notably, we identified diverse expression patterns; some cells exhibited positivity for
290 CD49f or CK14, indicating a basal phenotype. Mature luminal cells expressed EPCAM or CK8.
291 In contrast, other cells were positive for both CD49f and EPCAM, suggesting a luminal
292 progenitor phenotype (Figure 1A). These findings underscore the significance of the
293 heterogeneity within the isolated cells, emphasizing the need to capture the holistic impact of
294 the drug during *in vitro* treatment.

295 Based on our analysis of RNA-seq data from the *in vivo* clinical trial, six candidate genes were
296 selected among the top upregulated and downregulated ones (CCL18, CTSG, ABI3BP,
297 LAMA1, IL1b and WNT2) (Figure 1B and Figure S4). Consistent with our findings from the
298 RNA-seq data, the expression levels of CCL18 and CTSG were upregulated in the *in vitro*

299 experiment after longer treatment with higher concentrations, and the same was observed
300 following shorter treatment; except for one patient where CTSG expression showed a non-
301 significantly upregulated trend and remained unaffected, respectively. WNT2 demonstrated
302 upregulation in all patients when treated with low doses over a three-day period. Conversely, it
303 exhibited downregulation at higher concentrations during both treatment periods. Notably,
304 ABI3BP demonstrated considerable inter-patient variability; it was both up- and downregulated
305 following different concentrations seen in both treatment periods. LAMA1 was not aligned with
306 its downregulated pattern seen in the RCT cohort; it was mainly upregulated following
307 treatment *in vitro*. However, the secondly most downregulated DEG, IL1B, was significantly
308 reduced with higher concentrations of mifepristone following longer treatment and the same
309 was seen for two patients following shorter treatment. Interestingly, IL1B showed a significant
310 upregulation with low doses of mifepristone as compared to the untreated cells.

311

312 ***GEM-B is associated with breast carcinogenesis***

313 Given the recognized protooncogenic effect of progesterone in breast carcinogenesis, we aimed
314 to explore the enrichment of the GEM-B signature within breast cancer samples. To achieve
315 this objective, we systematically examined the expression patterns of our GEM-B signature in
316 the breast cancer dataset from The Cancer Genome Atlas (TCGA) using the R2 platform.

317 The signature was examined comparing the RNA-seq data of primary breast cancer tissue
318 (n=1101) to normal breast tissue (n=113). The results revealed a notable enrichment of GEM-
319 B in the TCGA data cohort when comparing cancerous to normal tissue. Specifically, 21 out of
320 the 27 signature genes exhibited significant and differential expression when comparing breast
321 cancer to normal breast tissue.

322 However, this enrichment displayed a dichotomy between cancerous and normal tissue. Out of
323 the 21 significantly correlated genes, 11 were enriched in normal breast tissue compared to

324 tumor (ABI3BP, CTSG, DPP4, CCL18, OSR2, GRIA3, MMP2, LAMA1, ASPRV1, IL1B,
325 PRR4), while the remaining 10 genes were significantly enriched in tumor tissue compared to
326 normal (COL1A1, COL5A1, COL1A2, COL3A1, WNT2, C1QTNF3, ADAMTS2, GXYLT2,
327 CCDC157, RP1), shown in Figure 2. Our findings underscore a substantial correlation between
328 GEM-B, comprising approximately 77.7% of the signature (21 out of 27 genes), and breast
329 carcinogenesis.

330

331 ***GEM-B is significantly correlated to PR expression status in breast cancer***

332 Having investigated the impact of mifepristone on healthy women, we aimed to explore the
333 potential relevance of the transcriptomic changes resulting from mifepristone treatment in our
334 cohort on PR status of the breast cancer cohort. The TCGA breast cancer dataset facilitated the
335 stratification of the PR status across the entire cohort, with 777 patients classified as PR-positive
336 and 337 patients as PR-negative. We conducted an in-depth analysis of the GEM-B gene list,
337 with a focus on delineating the PR status distinctions within the breast cancer datasets.

338 Out of the 27 genes within the GEM-B signature, 20 exhibited significant enrichment when
339 comparing the PR status categories. Notably, the majority of the enriched genes demonstrated
340 a robust correlation with PR expression. Specifically, 17 out of the 20 enriched genes (TPSAB1,
341 TPSB2, C1QTNF3, PIEZO2, CTSG, COL1A2, COL1A1, COL3A1, OSR2, ZNF620, ABI3BP,
342 MMP2, GXYLT2, COL5A1, CCDC157, RP1, ADAMTS2) exhibited higher expression levels
343 in PR-positive cancer tissue compared to PR-negative counterparts, while only 3 genes (CCL18,
344 SLC4A11, LAMA1) displayed heightened enrichment in PR-negative tissue (Figure 3).

345

346 ***Discussion***

347 In the present study, transcriptomic profiling and subsequent bioinformatics analyses were
348 performed to explore gene expression response associated with antagonizing progesterone in

349 breast tissue of healthy premenopausal women. The study focuses on role of endogenous
350 progesterone, enlightening the impact of mifepristone in driving the gene expression patterns
351 and ECM signaling pathways. The findings indicate a correlation with breast carcinogenesis
352 and PR expression status in breast cancer.

353
354 The cycle driven intermittent progesterone exposure followed by mammary gland regression
355 have been emphasized as important causes of tumorigenesis, as opposed to gradual and
356 continuous elevations during pregnancy or anovulation including lactational amenorrhea (1, 2).
357 RNA-seq from normal breast tissue in the Komen bank allies with progesterone's mitogenic
358 role. About 87% of the upregulated genes in the luteal phase, emphasize paracrine action of
359 RANKL, WNT4, and epiregulin as well as enriched functions of DNA replication, mitosis, and
360 DNA repair (23).

361
362 To address rising breast cancer incidence (8), exploring novel preventive agents is crucial.
363 Mifepristone, a widely studied PR modulator in various benign gynecological conditions and
364 breast cancer inhibition (12), may also hold potential in breast cancer prevention. In a rodent
365 model, mifepristone had a reverse effect on murine mammary stem cell expansion and
366 progesterone's paracrine effectors (24), although caution is needed in translating animal-based
367 results to human *in vivo* conditions.

368 Only two placebo-controlled trials have assessed the effect of mifepristone in normal
369 premenopausal human breast tissue *in vivo*. Exposure to mifepristone for two or three months,
370 significantly reduced Ki-67 expression in breast tissue (10), suggesting inhibition of breast
371 epithelial cell proliferation, and decreased mitotic age surrogate marker and luminal progenitor
372 cell fraction in all analyzed healthy controls (11).

373

374 Our findings highlight the enrichment of several pathways that directly regulate and drive
375 extracellular structure organization and function. ECM displays a pivotal role in tissue
376 homeostasis; consequently, dysregulation and destruction of ECM dynamics can lead to
377 tumorigenesis and cancer development (25, 26). During the menstrual cycle, it undergoes
378 hormonal regulation, affecting cell signaling and cancer pathways in the mammary gland and
379 the surrounding microenvironment (2). Clinically, HMD is positively associated with collagen,
380 ECM density, and the epithelial and stromal compartments, but negatively with fat tissue (8,
381 9). One of the main structural ECM proteins are collagen which represent a key factor that
382 provide tensile strength to the ECM (26) and in the present study, different collagens (COL1A1,
383 COL1A2, COL3A1, COL5A1) were significantly enriched upon mifepristone treatment.
384 Moreover, both collagen degradation and formation emerged as enriched pathways in our
385 material, reflecting an increased remodeling of the ECM compared to baseline. These findings
386 may reflect an ongoing adaptation to mifepristone and a longer treatment protocol might have
387 revealed the eventual direction in which the equilibrium would shift. Nevertheless, it seems that
388 the regulation of ECM plays a central role in progesterone action and progesterone receptor
389 antagonism in the breast.

390

391 A fundamental approach for assessing progesterone signaling involves assessment of the PR
392 expression and the subsequent downstream actions within the signaling pathway. The notable
393 enrichment of 20 genes within the GEM-B signature in PR-positive breast cancer tissue
394 underscores the substantial involvement of progesterone in the development of breast cancer.
395 Furthermore, our findings suggest that blocking progesterone signaling by mifepristone may
396 play a significant role in preventing the initiation of breast cancer. This prompts further avenues
397 for in-depth mechanistic studies, shedding light on the potential of mifepristone as both a
398 preventive and therapeutic strategy for breast cancer.

399

400 To the best of our knowledge, the present study is the first to explore the changes in the
401 transcriptomic landscape and its biological functions following progesterone antagonism with
402 mifepristone treatment in healthy breast tissue *in vivo*. The sample population originates from
403 a double-blind RCT (13), limiting the bias in the results and individual paired samples were
404 used, thus reducing the inter-individual variability. Next Generation Sequencing (NGS) was
405 used to identify DEGs, and the results were validated with RT-PCR, confirming the expression
406 pattern for all six randomly chosen genes; reinforcing that data derived from RNA-seq
407 technology is of robust nature and could be applied for further analyses. However, long-term
408 effects after treatment discontinuation were not elucidated due to lack of follow-up data. Based
409 on indications of ECM remodeling following mifepristone treatment, measurements of breast
410 stiffness and density through mammographies could provide further insights. Even though
411 breast cancer seems to arise predominantly from epithelial cells (2), the stroma of mammary
412 gland comprised mainly of the ECM emerged in our study to play a key role which is in line
413 with a plethora of investigations on breast cancer, even suggesting ECM remodeling as a
414 potential therapeutic target (26).

415

416 In conclusion, our investigation into PR modulation in normal breast tissue, following
417 mifepristone treatment, uncovers crucial alterations in gene expression patterns. The observed
418 shifts in gene expression, in pathways related to ECM organization, point to the complicated
419 involvement of ECM dynamics. The significant correlation of our enriched signature with the
420 PR expression in breast cancer emphasizes the downstream impact of progesterone.
421 Undoubtedly, comprehensive studies specifically designed to delve into the detailed molecular
422 landscape alterations induced by mifepristone treatment could shed light into the molecular

423 actions of progesterone. Furthermore, such studies may explore whether antagonizing
424 progesterone could accord protective properties in the breast.

425

426 **Acknowledgments**

427 We would like to thank research midwife Eva Broberg for patient recruitment support and Dr
428 Birgitte Wilczek for offering her kind help in collecting breast biopsies. Our thanks also go to
429 Dr. Angelique Flöter Rådestad and Dr. Inkeri Leonardsson Schultz for their contribution in
430 providing breast samples from healthy women who underwent reduction mammoplasty
431 surgeries.

432

433 **References**

- 434 1. Coelingh Bennink HJT, Schultz IJ, Schmidt M, Jordan VC, Briggs P, Egberts
435 JFM, et al. Progesterone from ovulatory menstrual cycles is an important cause of breast
436 cancer. *Breast cancer research : BCR.* 2023;25(1):60.
- 437 2. Atashgaran V, Wrin J, Barry SC, Dasari P, Ingman WV. Dissecting the Biology
438 of Menstrual Cycle-Associated Breast Cancer Risk. *Frontiers in oncology.* 2016;6:267.
- 439 3. Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the
440 normal breast and its implications for cancer development. *Molecular and cellular
441 endocrinology.* 2018;466:2-14.
- 442 4. Pedroza DA, Subramani R, Lakshmanaswamy R. Classical and Non-Classical
443 Progesterone Signaling in Breast Cancers. *Cancers.* 2020;12(9).
- 444 5. Skibinski A, Kuperwasser C. The origin of breast tumor heterogeneity.
445 *Oncogene.* 2015;34(42):5309-16.
- 446 6. Brisken C. Progesterone signalling in breast cancer: a neglected hormone
447 coming into the limelight. *Nature reviews Cancer.* 2013;13(6):385-96.
- 448 7. Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Progesterone and Breast
449 Cancer. *Endocrine reviews.* 2020;41(2):320-44.
- 450 8. Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer
451 prevention. *Nature reviews Cancer.* 2020;20(8):417-36.
- 452 9. Ironside AJ, Jones JL. Stromal characteristics may hold the key to
453 mammographic density: the evidence to date. *Oncotarget.* 2016;7(21):31550-62.
- 454 10. Engman M, Skoog L, Söderqvist G, Gemzell-Danielsson K. The effect of
455 mifepristone on breast cell proliferation in premenopausal women evaluated through fine
456 needle aspiration cytology. *Human reproduction (Oxford, England).* 2008;23(9):2072-9.
- 457 11. Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, et al.
458 Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
459 *Genome medicine.* 2022;14(1):64.

- 460 12. Islam MS, Afrin S, Jones SI, Segars J. Selective Progesterone Receptor
461 Modulators-Mechanisms and Therapeutic Utility. *Endocrine reviews*. 2020;41(5).
- 462 13. Papaikonomou K, Kopp Kallner H, Söderdahl F, Gemzell-Danielsson K.
463 Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for
464 improved bleeding control - a randomized controlled trial. *Human reproduction (Oxford,*
465 *England)*. 2018;33(11):2002-9.
- 466 14. Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R.
467 Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc*. 2014;9(1):171-81.
- 468 15. von Grothusen C, Frisendahl C, Modhukur V, Lalitkumar PG, Peters M,
469 Faridani OR, et al. Uterine fluid microRNAs are dysregulated in women with recurrent
470 implantation failure. *Human reproduction (Oxford, England)*. 2022;37(4):734-46.
- 471 16. Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis
472 results for multiple tools and samples in a single report. *Bioinformatics*. 2016;32(19):3047-8.
- 473 17. Love MI, Huber W, Anders S. Moderated estimation of fold change and
474 dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
- 475 18. Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al.
476 g:Profiler-a web server for functional interpretation of gene lists (2016 update). *Nucleic acids*
477 *research*. 2016;44(W1):W83-9.
- 478 19. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, et al.
479 Reactome knowledgebase of human biological pathways and processes. *Nucleic acids*
480 *research*. 2009;37(Database issue):D619-22.
- 481 20. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al.
482 Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.
483 *Nature communications*. 2019;10(1):1523.
- 484 21. R2: Genomics Analysis and Visualization Platform [Available from:
485 <http://r2.amc.nl>].
- 486 22. Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M,
487 et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex
488 epithelial lineages. *Nature communications*. 2020;11(1):1711.
- 489 23. Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CA, Doxey DK, et al. Next-
490 generation transcriptome sequencing of the premenopausal breast epithelium using specimens
491 from a normal human breast tissue bank. *Breast cancer research : BCR*. 2014;16(2):R26.
- 492 24. Ranjan M, Lee O, Cottone G, Mirzaei Mehrabad E, Spike BT, Zeng Z, et al.
493 Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of
494 progesterone action in the mouse mammary gland. *Breast cancer research : BCR*.
495 2021;23(1):78.
- 496 25. Walker C, Mojares E, Del Río Hernández A. Role of Extracellular Matrix in
497 Development and Cancer Progression. *International journal of molecular sciences*.
498 2018;19(10).
- 499 26. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in
500 development and disease. *Nature reviews Molecular cell biology*. 2014;15(12):786-801.

501

502

503

504

505

506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523

524 ***Figure Captions***

525 **Figure 1. A)** Characterization of normal primary breast cell (Basal, luminal progenitor &
526 Mature cells). The upper panel displays immunofluorescent images depicting breast cells
527 stained with CD49f (green) and EPCAM (red), while the lower panel showcases cells stained
528 with CK14 (red) and CK8 (green). Scale bars indicate 50 μ m. DAPI was used to detect the
529 nuclei. **B)** Assessment of relative gene expression in normal primary breast cells. Real time
530 PCR analysis was conducted on selected genes (CCL18, CTSG, ABI3BP, WNT2, IL1b, and

531 LAMA1) to evaluate their expression levels in normal primary breast cells treated with varying
532 concentrations of mifepristone (control, 5 μ M, 50 μ M, 100 μ M) for a three-day duration.
533 Statistical significance is denoted as follows: * $p < 0.0001$; ** $p < 0.01$; *** $p < 0.001$;
534 **** $p < 0.0001$.

535
536 **Figure 2.** GEM-NB signature enrichment in breast cancer. Utilizing the R2 platform and the
537 TCGA breast cancer dataset, the expression patterns of each gene within the GEM-NB signature
538 were examined. Comparative analysis involved RNA-seq data between two the groups of
539 primary breast cancer tissue (n=1101) and normal breast tissue (n=113).

540
541 **Figure 3.** Mifepristone driven transcriptomic changes in the context of PR status in breast
542 cancer. Employing the R2 platform and the TCGA breast cancer dataset, seventeen genes within
543 the GEM-NB signature show significant enrichment in PR positive cohort, whereas three genes
544 were enriched in PR negative cohort. The results are presented as a heatmap illustrating the
545 mean log₂ values for each gene, with P values indicated on a log₁₀ scale. The analysis involved
546 RNA-seq data from 1114 breast cancer tissues, comparing PR-positive cases (n=777) to PR-
547 negative cases (n=337).

548
549 **Supplemental figure 1.** Study flow diagram.

550 *Paired biopsies = baseline plus follow-up breast biopsies from the same patient.

551
552 **Supplemental figure 2. A)** Volcano plot showing the distribution of the differentially
553 expressed genes (DEGs) between breast samples from baseline and after mifepristone
554 treatment. X-axis represent log₂ fold change and Y-axis represent logFDR (adjusted p-value).
555 Black vertical lines show log fold change of - 2 and 2 while the horizontal black line represents

556 a p-value of 0.05. The points represent genes; red for the upregulated DEGs, blue for the
557 downregulated DEGs and grey for the non-differentially expressed genes. **B)** Assessment of
558 relative gene expression before and after mifepristone treatment. Utilizing the RNA isolated
559 from the breast tissue obtained from RCT, Real time PCR analysis was conducted on selected
560 genes (ADAMTS2-1, CCL18, MMP2, COL1A1, COL1A2 and COL3A1) show a significant
561 upregulation with mifepristone treatment in breast. This is in line with RNA sequencing data.
562 *p<0.05; **p<0.01; ***p<0.001.

563
564 **Supplemental figure 3.** Network of enriched terms for GEM-NB genes as determined by
565 Metascape-designet analysis; showing the significance enrichment of extracellular matrix
566 remodeling pathways. (A) Nodes colored by cluster ID; nodes that share the same cluster ID
567 are typically close to each other. (B) Nodes colored by p-value, where terms containing more
568 genes tend to exhibit more significant p-values.

569
570 **Supplemental figure 4.** Assessment of relative gene expression in normal primary breast cells.
571 Real time PCR analysis was conducted on selected genes (CCL18, CTSG, ABI3BP, WNT2,
572 IL1b, and LAMA1) to evaluate their expression levels in normal primary breast cells treated
573 with varying concentrations of mifepristone (control, 5µM, 50µM, 100µM) for one day
574 duration. Statistical significance is denoted as follows: *p<0.0001; **p<0.01; ***p<0.001;
575 ****p<0.0001.

576
577 **Tables**
578 **Table 1.** Top 15 enriched gene ontology terms of differentially expressed upregulated genes as
579 determined by Gene Ontology (GO) analyses.

Term ID	Description	FDR (padj)
---------	-------------	------------

Biological Process

GO:0030198	Extracellular matrix organization	2.21E-08
GO:0043062	Extracellular structure organization	2.21E-08
GO:0030199	Collagen fibril organization	6.95E-07
GO:0032963	Collagen metabolic process	1.76541E-05
GO:0071230	Cellular response to amino acid stimulus	0.000123191

Cellular

Component

GO:0062023	Collagen-containing extracellular matrix	4.78E-12
GO:0031012	Extracellular matrix	4.59E-11
GO:0098643	Banded collagen fibril	1.13E-08
GO:0005583	Fibrillar collagen trimer	1.13E-08
GO:0098644	Complex of collagen trimers	1.08E-07

Molecular

Function

GO:0048407	Platelet-derived growth factor binding	2.76E-08
GO:0030020	Extracellular matrix structural constituent conferring tensile strength	4.1495E-06
GO:0005201	Extracellular matrix structural constituent	1.75112E-05
GO:0004252	Serine-type endopeptidase activity	1.75112E-05
GO:0017171	Serine hydrolase activity	2.17779E-05

FDR=false discovery rate

580
581

582 **Supplemental table 1.** Baseline characteristics of women contributing to paired breast
583 biopsies, before and after mifepristone treatment, expressed as median (range).


584

585 **Supplemental table 2.** Differentially expressed genes with mifepristone treatment.

586

587 **Supplemental table 3.** Top 10 enriched pathways of the upregulated differentially expressed
588 genes as determined by Reactome pathway analysis.

A



B

